Fulcrum Therapeutics Inc (FULC) — Cash Flow-to-Debt Ratio
Fulcrum Therapeutics Inc (FULC) has a Cash Flow-to-Debt Ratio of -0.86x as of September 2025, meaning its operating cash flow of $-14.19 Million could theoretically repay -1% of its total liabilities ($16.49 Million) in one year. See how much free cash does Fulcrum Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Fulcrum Therapeutics Inc Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Fulcrum Therapeutics Inc across 8 annual periods. Also explore how fast is Fulcrum Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Fulcrum Therapeutics Inc (2017–2024)
Year-by-year debt coverage analysis for Fulcrum Therapeutics Inc. For market capitalisation and broader financial context, see FULC stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.13x | $-2.22 Million | $17.68 Million | ▲ +96.9% |
| 2023 | -4.04x | $-90.97 Million | $22.50 Million | ▼ -15.6% |
| 2022 | -3.50x | $-97.05 Million | $27.74 Million | ▼ -4.6% |
| 2021 | -3.35x | $-78.48 Million | $23.46 Million | ▼ -114.4% |
| 2020 | -1.56x | $-53.66 Million | $34.40 Million | ▲ +8.0% |
| 2019 | -1.70x | $-39.48 Million | $23.29 Million | ▲ +26.6% |
| 2018 | -2.31x | $-22.56 Million | $9.77 Million | ▲ +65.3% |
| 2017 | -6.65x | $-20.07 Million | $3.02 Million | — |